综合疗法治疗子宫内膜异位症痛经的临床疗效观察
|
摘要
目的：观察内服中药联合局部超声电导仪治疗子宫内膜异位症痛经的疗效,总结综合疗法治疗子宫内膜异位症所致痛经的临床经验。
方法：40例子宫内膜异位症痛经患者,辨证属肾虚血瘀型,随机分为治疗组和对照组,治疗组20例,对照组20例。对照组采用口服中药内异缓痛汤的治疗方法,治疗组采用口服中药内异缓痛汤加局部超声电导仪的治疗方法。两组均采用慢性疼痛(痛经)分级问卷、痛经程度评分标准及临床疗效评定法进行评估。观察治疗前、后两组患者的痛经改善程度,评价本方法的干预作用。观察数据用SPSS13.0统计分析软件处理。
结果：治疗组和对照组在治疗子宫内膜异位症痛经总疗效的比较,总有效率分别为85.00%和80.00%,两组比较有统计学意义(P<0.01),治疗组在治疗子宫内膜异位症痛经的总疗效优于对照组。对两组进行自身前后比较,慢性疼痛(痛经)分级问卷积分、痛经程度评分与治疗前相比,均有统计学意义(P<0.01)。
结论：综合疗法能有效地改善子宫内膜异位症所致痛经的情况,有很好的止痛效果。
Objective:To observe the clinical evaluation of combined modality therapy treating dysmenorrhea caused by EMs.
Methods:40 patients complained with dysmenorrhea were randomly divided into treatment group(20 patients) and control group(20 patients). Control group used the therapy for oral decoction, treatment group used oral decoction and ultrasound conductimeter treatment. All patients were assessed with chronic pain(dysmenorrhea) grade questionnaire, dysmenorrhea scoring criteria and clinic curative effect assessment.
Results:The comparation of overall efficacy of endometriosis between treatment group and control group,the total effective rate were 85% and 80% respectively,there was statistically difference (P<0.01).In overall efficacy of endometriosis, treatment group is more effective than control group. Comparation with the two groups own respectively,their chronic pain (dysmenorrhea) classification questionnaire points,dysmenorrhea severity score compared with those before treatment,were statistically significant.
Conclusion:combined modality therapy has significant therapeutic effects on patients with dysmenorrhea caused by EMs,it is valuable for widely used in clinic.
方法：40例子宫内膜异位症痛经患者,辨证属肾虚血瘀型,随机分为治疗组和对照组,治疗组20例,对照组20例。对照组采用口服中药内异缓痛汤的治疗方法,治疗组采用口服中药内异缓痛汤加局部超声电导仪的治疗方法。两组均采用慢性疼痛(痛经)分级问卷、痛经程度评分标准及临床疗效评定法进行评估。观察治疗前、后两组患者的痛经改善程度,评价本方法的干预作用。观察数据用SPSS13.0统计分析软件处理。
结果：治疗组和对照组在治疗子宫内膜异位症痛经总疗效的比较,总有效率分别为85.00%和80.00%,两组比较有统计学意义(P<0.01),治疗组在治疗子宫内膜异位症痛经的总疗效优于对照组。对两组进行自身前后比较,慢性疼痛(痛经)分级问卷积分、痛经程度评分与治疗前相比,均有统计学意义(P<0.01)。
结论：综合疗法能有效地改善子宫内膜异位症所致痛经的情况,有很好的止痛效果。
Objective:To observe the clinical evaluation of combined modality therapy treating dysmenorrhea caused by EMs.
Methods:40 patients complained with dysmenorrhea were randomly divided into treatment group(20 patients) and control group(20 patients). Control group used the therapy for oral decoction, treatment group used oral decoction and ultrasound conductimeter treatment. All patients were assessed with chronic pain(dysmenorrhea) grade questionnaire, dysmenorrhea scoring criteria and clinic curative effect assessment.
Results:The comparation of overall efficacy of endometriosis between treatment group and control group,the total effective rate were 85% and 80% respectively,there was statistically difference (P<0.01).In overall efficacy of endometriosis, treatment group is more effective than control group. Comparation with the two groups own respectively,their chronic pain (dysmenorrhea) classification questionnaire points,dysmenorrhea severity score compared with those before treatment,were statistically significant.
Conclusion:combined modality therapy has significant therapeutic effects on patients with dysmenorrhea caused by EMs,it is valuable for widely used in clinic.
引文
[1]Szendei GA. Endometriosis in Hungary[J]. Gynecol Endocrinol,2009,25 (11):694-700.
[2]Szpak R, Bugala-Szpak J, et al. Health-related quality of life in women with endometriosis[J]. Wiad Lek, 2009,62 (2):129-134.
[3]郎景和,谭先杰.第七届国际子宫内膜异位症会议纪要[J].国外医学妇产科学分册,2001,28(1)：40-43.
[4]Tsutsumi O. Assessment of human contamination of estrogenic endocrine-disrupting chemicals and their risk for human reproduction[J].J Steroid Biochem Mol Biol,2005,93 (2-5):325-330.
[5]郎景和.关于子宫内膜异位症的再认识及其意义[J].中国工程科学2009,(10)：138-142.
[6]Luisi S, Lazzeri L, Ciani V, et al. Endometriosis in Italy:from cost estimates to new medical treatment[J]. Gynecol Endocrinol,2009,25 (11):734-40.
[7]Garcia Manero M, Olartecoechea B, Royo Manero P, et al. Endometriosis[J]. Rev Med Univ Navarra, 2009,53 (2):4-7.
[8]王建华.子宫内膜异位症在位内膜酶分子表达研究进展[J].国外医学妇产科学分册,2004,31(2)：67-70.
[9]Ishihara H, Kitawaki J, Kado N, et al. Gonadotropin-releasing hormone agonist and danazol normalize cytochrome P-450 expression in eutopic endometrium from women with endometriosis,adenomyosis,or leiomyomas[J].Fertil Steril,2003,79 (Suppl 1):735-742.
[10]Zeitoun K, Takayama K, Michael MD, et al. Stimulation of aromatase P450 promoter(Ⅱ) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-Ⅰ and chicken ovalbumin upstream promoter transcription fator to the same cis-acting element[J]. Mol Endocrinol,1999,13 (2):239-253.
[11]Noble LS, Takayama K, Putman JM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells[J]. J Clin Endocrinol Metab,1997,82 (2):600-606.
[12]Tamura M, Deb S, Sebastian S, et al. Estrogen up-regulates cyclo-oxygenase-2 via estrogen receptor in human uterin microvascular endothelial cells[J]. Fertil Steril,2004,81 (5):1351-1356.
[13]Yang S, Fang Z, Suzuki T, et al. Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins(C/EBPs):decreased C/EBP betain endometriosis is associated with overexpression of aromatase[J]. J Clin Endocrinol Metab,2002,87 (5):2336-2345.
[14]Gurates B, Sebastian S, Yang S, et al. WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells[J]. J Clin Endocrinol Metab,2002,87 (9):4369-4377.
[15]Holloway AC, Stys KA, Foster WG. DDE-induced changes in aromatase activity in endometrial stromal cells in culture[J]. Endocrine,2005,27 (1):45-50.
[16]Casey M L, MacDonald P C, Andersson S.17p-hydroxysteroid dehydrogenase type 2 chromosomal assignment and progestin regulation of gene expression in human endometrium[J]. J Clin Invest,1994, 94 (5):2135-2141.
[17]Yang S, Fang Z, Gurates B, et al. Stromal PRs mediate induction of 17β-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium:A paracrine mechanism for in-activation of E2[J]. Mol Endocrinol,2001,15 (12):2093-2105.
[18]曲军英,欧湘红,等.17 β-羟甾类固醇脱氢酶Ⅱ在异位子宫内膜的表达缺陷及其意义[J].福建医科大学学报,2008,42(1)：80-82.
[19]Mylonas I, Jeschke U, Shabani N, et al. Immunohistochemical analysis of estrogen receptor alpha, estrogen receptor beta and progesterone receptor in normal human endometrium[J]. Acta Histochem, 2004,106 (3):245-252.
[20]Bain DL, Franden MA, McManaman JL, et al. The N-terminal region of human progesterone B-receptors:biophysical and biochemical comparison to A-receptors[J]. J Biol Chem,2001,276 (26):23825-23831.
[21]Selak V, Farquhar C, Prentice A, et al. Danazol for pelvic pain associated with endometriosis[J]. Cochrane Database Syst Rev,2000, (2):CD000068.
[22]Mulayim N, Palter SF, Kayisli UA, et al. Chemokine receptor expression in human endometrium[J]. Biol .Reprod,2003,68 (5):1491-1495.
[23]Kayisli UA, Mahutte NG, Arici A. Uterine chemokines in reproductive physiology and pathology[J]. Am J Reprod Immunol,2002,47 (4):213-221.
[24]Mulayim N, Savlu A, Guzeloglu-kayisi O, et al. Regulation of endometrial stromal cell matrix metalloproteinase activity and invasiveness by interleukin-8[J]. Fertil Steril,2004,81 (Suppl1):904-911.
[25]Calhaz-Jorge C, Costa AP, Santos MC, et al. Peritoneal fluid concentrations of interleukin-8 in patients with endometriosis depend on the severity of the disorder and are higher in the luteal phase[J]. Hum Reprod,2003,18(3):593-597.
[26]黄丛笑,刘萍,张居民.纤维粘连蛋白及其受体整合素β1在子宫内膜异位症中的表达[J].中国实用医药,2009,4(1)：124.
[27]史颖莉,李大金.趋化因子在子宫内膜异位症发生与发展中的作用[J].国外医学妇产科学分册,2004,31(5)：305-308.
[28]Sakamoto Y, Harada T, Horie S, et al. Tumor necrosis factor-alpha-induced interleukin-8 (IL-8)expression in endometriotic stromal cells,probably through nuclear factor-kappa B activation:gonadotropin-releasing hormone agonist treatment reduced IL-8 expression[J]. J Clin Endocrinol Metab,2003,88 (2):730-735.
[29]熊苗,屠菊红,赵爱民.趋化因子及其受体与子宫内膜异位症的关系[J].中国妇幼健康研究,2006,17(6)：516-518.
[30]郭小明,唐显赫,张学辉.单核细胞趋化蛋白在子宫内膜异位症中的作用研究进展[J].中国煤炭工 业医学杂志,2008,11(2)：278-279.
[31]Kharfi A, Akoum A. Correlation between decreased type-Ⅱ interleukin-1 receptor and increased monocyte chemotactic protein-1 expression in the endometrium of women with endometriosis[J]. Am J Reprod Immunol,2001,45 (4):193-199.
[32]Hornung D, Bentzien F, Wallwiener D, et al. Chemokine bioactivity of RANTES in endometriotic and normal endometrial stromal cells and peritoneal fluid[J]. Mol Hum Reprod,2001,7 (2):163-168.
[33]Dechaud H, Witz CA, Montoya-Rodriguez IA, et al. Mesothelial cell-associated hyaluronic acid promotes adhesion of endometrial cells to mesothelium[J]. Fertil Steril,2001,76 (5):1012-1018.
[34]Whiteside EJ, Jackson MM, Herington AC, et al. Matrix metalloproteinases-9 and inhibitor of metalloproteinases-3 are key regulators of extracelluar matrix degradation by mouse embryos[J]. Biol Reprod,2004,64 (5):1331-1337.
[35]Kokorine I, Eeckhout Y, Nisolle M, et al. Expression of interstitial collagenase (matrix metalloproteinase-1) is related to the activity of human endometriotic lesions[J]. Fertil Steril,1997,68 (2):246-251.
[36]Kim HO, Yang KM, Kang IS, et al. Expression of CD44s,vascular endothelial growth factor, matrix metalloproteinase-2 and Ki-67 in peritonea,rectovaginal and ovarian endometriosis[J]. J Reprod Med, 2007,52 (3):207-213.
[37]Ramon L, Gilabert-estelles J, Castello R, et al. mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay[J]. Hum Reprod,2005,20 (1):272-278.
[38]Collette T, Maheux R, Mailloux J, et al. Increased expression of matrix metalloproteinase-9 in the eutopic endometrial tissue of women with endometriosis[J]. Hum Reprod,2006,21 (12):3059-3067.
[39]Bourguignon LY, Gunja-Smith Z, Iida N, et al. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breas cancer cells[J].J Cell physiol,1998,176 (1):206-215.
[40]Laudanski P, Szamalowjcz J, Ramel P. Matrix metalloproteinase-13 and membrane type-1 matrix metalloproteinase in peritoneal fluid of women with endometriosis [J]. Gynecol Endocrinol,2005,21 (2):106-110.
[41]Kang S, Wang Y, Zhang JH, et al. Single nucleotide polymorphism in the matrix metalloproteinases promoter is associated with susceptibility to endometriosis and adenomyosis[J]. Zhonghua Fu Chan Ke Za Zhi,2005,40 (9):601-604.
[42]Shan K, Lian-Fu Z, Hui D, et al. Polymorphisms in the promoter regions of the matrix metalloproteinases-7,-9 and the risk of endometriosis and adenomyosis in China[J]. Mol Hum Reprod, 2006,12 (1):35-39.
[43]Chung HW, Wen Y, Chun SH, et al. Matrix metaloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in eutopic and eutopic endometrium in women with endometriosis:a rationale for endometriotic invasiveness[J]. Fertil Steril,2004,75 (1):152-159.
[44]Goffin F, Munaut C, Frankenne F, et al. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium[J]. Biol Reprod,2003,69 (3):976-984.
[45]周小会,李兆艾.子宫内膜异位症患者腹腔液中MMP-1和TMP-1的检测[J].江苏医药,2007,33(1)：32-33.
[46]沈蓉,田永杰.MMP-9、TIMP-1在子宫内膜异位症患者子宫内膜中的表达及意义[J].山东医药,2006,46(17)：20-22.
[47]Sillem M, Prifti S, Koch A, et al. Regulation of matrix metalloproteinases and their inhibitors in uterine endometrial cells of patients with and without endometriosis[J]. Eur J Obstet Gynecol Reprod Biol,2001, 95 (2):167-174.
[48]Noguchi Y, Sato T, Hirata M, et al. Identification and characterization of extracellular matrix metalloproteinase inducer in human endometrium during the menstrual cycle in vivo and in vitro[J]. J Clin Endocrinol Metab,2003,88 (12):6063-6072.
[49]刘木彪,何援丽,麦冬先.子宫内膜异位症患者腹腔液血管内皮生长因子与内抑素的表达[J].第一军医大学学报,2004,24(1)：69-71.
[50]Mahnke JL, Dawood MY, Huang JC. Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis[J]. Fertil Steril,2000,73 (1):166-170.
[51]Nap AW, Griffioen AW, Dunselman GA, et al. Antiangiogenesis therapy for endometriosis [J]. J Clin Endocrinol Metab,2004,89 (3):1089-1095.
[52]Saitoh Y, Yaginuma Y, Ishikawa M. Analysis of Bcl-2,Bax and Survivin genes in uterine cancer[J]. Int J Oncol,1999,15 (1):137-141.
[53]Ferrero S, Gillott DJ, Anserini P, et al. Methodological concerns regarding levels of vascular endothelial growth factor(VEGF) in serum of patients with endometriosis [J]. Hum Reprod,2008,19(1):220-221.
[54]van de Kerkhof PC, Rulo HF, van Pelt JP, et al. Expression of endoglin in the transition between psoriatic uninvolved and involved skin[J]. Acta Derm Venereol,1998,78 (1):19-21.
[55]任旭,何援利,彭冬先.缺氧诱导因子-1 α在子宫内膜异位症中的表达与微血管密度的关系[J].广东医学,2007,28(2)：229-231.
[56]Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis[J]. J Natl Cancer Inst,2001,93 (4):309-314.
[57]Fujimoto J, Sakaguchi H, Hirose R, et al. Angiogenesis in endometriosis and angiogenic factors[J]. Gynecol Obstet Invest,1999,48(1):14-20.
[58]Talbi S, Hamilton AE, Vo KC, et al. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women[J]. Endocrinology,2006,147 (3):1097-1121.
[59]Brown LF, Detmar M, Tognazzi K, et al. Uterine smooth muscle cells express functional receptors(flt-1 and KDR)for vascular permeability factor/vascular endothelial growth factor[J]. Lab Invest,1997,76 (2):245-255.
[60]Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential[J].Microvasc Res,2002,64 (2):326-333.
[61]Matsuzaki S, Canis M, Yokomizo R, et al. Expression of erythropoietin and erythropoietin receptor in eritoneal endometriosis[J]. Hum Reprod,2003,18 (1):152-156.
[62]胡瑞成,谭双香.缺氧诱导因子1蛋白质水平及活性的调节[J].国外医学分子生物学分册,2003,3：99-102.
[63]Hayrabedyan S, Kyurkchiev S, Kehayov I. Endoglin (cd105) and S100A13 as markers of active angiogenesis in endometriosis[J]. Reprod Biol,2005,5 (1):51-67.
[64]Zhou H, Wang W, LuoY. Contributions of disulfide bonds in a nested pattem to the structure,stability,and biological functions of endostatin[J]. J Biol Chem,2005,280 (12):11303-11312.
[65]Liu MB, He YL, Peng DX. Expression of vascular endothelial growth factor and endostain in peritoneal fluid of patients with endometriosis[J]. Di Yi Jun Yi Da Xue Xue Bao,2004,24 (1):69-71.
[66]Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancenassociation with p53 alterations,tumor angiogenesis,and tumor progression[J]. J Natl Cancer Inst,1997,89 (3):219-227.
[67]Maeda K, Nishiguchi Y, Yashiro M, et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma[J]. Int J Mol Med,2000,5 (4):373-378.
[68]谭先杰,郎景和,刘东远,等.血管内皮生长因子及血小板反应素在异位子宫内膜组织中的表达[J].中华妇产科杂志,2001,36(12)：727-730.
[69]王云霞,李亚里,黄靖香.凋亡调节基因bcl-2,bax和fas在子宫内膜异位症中的表达[J].解放军医学杂志,2001,26(1)：69-70.
[70]Kuida K, Haydar TF, Kuan CY, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase-9[J]. Cell,1998,94 (3):325-337.
[71]Dmowski WP, Ding J, Shen J, et al. Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis[J]. Hum Reprod,2001,16 (9):1802-1808.
[72]王平,边爱平,段瑞丽.子宫内膜异位症患者子宫内膜caspase-3的表达研究[J].实用诊断与治疗杂志,2006,20(4)：242-243.
[73]Ueda M, Yamashita Y, Takehara M, et al. Survivin gene expression in endometriosis[J]. J Clin Endocrinol Metab,2002,87 (7):3452-3459.
[74]Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p 16 (IN K4a) and Cdk2/cyclin E complex activation[J]. Oncogene,2000,19 (29):3225-3234.
[75]Fraser AG, James C, Evan GI, et al. Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis[J]. Curr Biol,1999,9(6):292-301.
[76]Sanna MG, da Silva Correia J, Ducrey O, et al. IAP suppression of apoptosis involves distinct mechanisms:the TAK1/JNK1 signaling cascade and caspase inhibition[J]. Mol Cell Biol,2002,22 (6): 1754-1766.
[77]王春芳,边爱平.Livin和Caspase-9在子宫内膜异位症中的表达[J].中国妇产科临床杂志,2009,10(2)：127-130.
[78]Kalu E, Sumar N, Giannopoulos T, et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis[J]. J Obstet Gynaecol Res,2007,33 (4):490-495.
[79]Had RS, Fleming SD, Bebington CR, et al. Ubiquitin is associated with the survival of ectopic stromal cells in endometriosis[J]. Reprod Biol Endocrinol,2004,2 (1):69-73.
[80]Banerjee M, Dinda AK, Sinha S, et al. C-myc oncogene expression and cell proliferation in mixed oligo-astrocytoma[J]. Int Cancer,1996,65 (6):730-733.
[81]刘俊达,张靖莲.细胞凋亡研究促进新药开发的展望[J].中国新药杂志,1999,8(5)：298.
[82]Bischoff FZ, Heard M, Simpson JL. Somatic DNA alterations in endometriosis:high frequency of chromosome 17 and p53 loss in late-stage endometriosis[J]. J Reprod Immunol,2002,55 (1-2):49-64.
[83]Braun DP, Ding J, Shen J, et al. Relationship between apoptosis and the number of macrophages in eutopic endometrium from womenwith and without endometriosis[J]. Fertil Steril,2002,78 (4):830-835.
[84]Mutter GL, Lin MC, Fitzgerald JT, et al. Changes in endometrial PTEN expression throughout the human menstrual cycle[J]. J Clin Endocrinol Metab,2000,85 (6):2334-2338.
[85]Nishida M, Nasu K, Ueda T, et al. Endometriotic cells are resistant to interferon-gamma-induced cell growth inhibition and apoptosis:a possible mechanism involved in the pathogenesis of endometriosis[J]. Mol Hum Reprod,2005,11 (1):29-34.
[86]Van Langendonckt A, Casanas Roux F, Donnez J, et al. Oxidative stress and petitoneal endometriosis[J]. Fertil Steril,2002,77 (5):861-870.
[87]Ota H, Igarashi S, Tanaka T. Xanthine oxidase in eutopic and ectopic endometrium in endometriosis and adenomyosis[J]. Fertil Steril,2001,75 (4):785-790.
[88]Gallinelli A, Chiossi G, Giannella L, et al. Different concentrations of interleukins in the peritoneal fluid of women with endometriosis:relationships with lymphocyte subsets[J]. Gynecol Endocrinol,2004,18 (3):144-151.
[89]Oosterlynck DJ, Meuleman C, Waer M, et al. The natural killer activity of peritoneal fluid lymphocytes is decreased in women with endometriosis[J]. Fertil Steril,1992,58 (2):290-295.
[90]令狐华,徐小蓉,卞度宏.子宫内膜异位症患者外周血及腹腔中自然杀伤细胞活性的测定[J].中华妇产科杂志,1996,31：586-589.
[91]Prefumo F, Semino C, Melioli G, et al. A defective expression of ICAM-1 (CD54) on secretory endometrial cells is associated with endometriosis[J]. Immunol Lett,2002,80 (1):49-53.
[92]Berkkanoglu M, Arici A. Immunology and endometriosis[J]. Am J Reprod Immunol,2003,50(1):48-59.
[93]Kayisli UA, Mahutte NG, Arici A. Uterine chemokines in reproductive physiology and pathology[J]. Am J Reprod Immunol,2002,47 (4):213-221.
[94]Koike H, Egawa H, Ohtsuka T, et al. Correlation between dysmenorrheic severity and prostaglandin production in women with endometriosis[J]. Prostaglandins Leukot Essent Fatty Acids,1992,46 (2): 133-137.
[95]孙笑,周应芳.TGF-β1与子宫腺肌病痛经的相关性研究实验与基础研究[J].中国妇幼保健,2008,23(1)：73-74.
[96]江森.子宫内膜异位症研究的进展[J].中华妇产科杂志,1994,10(2)：624.
[97]Tahara A, Tsukada J, Tomura Y, et al. Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells[J]. British Journal of Pharmacology,2000,129 (1):131-139.
[98]Gimpl G, Fshrenholz F. The Oxytocin Receptor System:Structure,Function,and Regulation[J]. Physiological Reviews,2001,81(2):629-683.
[99]Oku H, Tsuji Y, Kashiwamura SI, et al. Role of IL-18 in pathogenesis of endometriosis[J]. Hum Reprod, 2004,19 (3):709-714.
[100]岳天孚,刘晓玫.子宫内膜异位症与盆腔痛[J].中华实用妇产科与产科杂志,1999,10(3)585-587.
[101]徐传花,夏桂成.夏桂成治疗子宫内膜异位症所致痛经的经验[J].中国中医药信息杂志,2003,10(5)：70.
[102]卫爱武.韩冰治疗子宫内膜异位症经验[J].北京中医杂志,2003,22(1)：13.
[103]岳小强,史学文.子宫内膜异位症从脾论治探讨[J].时珍国医国药,2001,12(3)：238.
[104]王雨波.温阳化瘀法治疗盆腔子宫内膜异位症疗效观察[J].四川中医,2007,25(5)：79-80.
[105]付淑秀,路臻,高天雨.补脾祛瘀方治疗子宫内膜异位症46例[J].中医药临床杂志,2007,19(3)：230.
[106]黄艳辉,曹立幸,司徒仪.莪棱胶囊治疗气滞血瘀型子宫内膜异位症临床研究[J].上海中医药杂志,2008,42(3)：46-48.
[107]徐玲,焦锟.宣郁通经汤化裁治疗肝郁血热型痛经48例[J].江苏中医药,2008,40(11)：69.
[108]毕蓉蓉.中医治疗子宫内膜异位症探讨[J].中国血液流变学杂志,2001,11(1)：69-71.
[109]吴凡,祖玉梅.辨证治疗子宫内膜异位症53例[J].辽宁中医杂志,1997,24(3)：122-123.
[110]张灵芳,罗杏娟.王金生治疗子宫内膜异位症经验[J].现代中西医结合杂志,2007,16(25)：3710.
[111]张俐,刘平,刘红艳.中药治疗子宫内膜异位症29例[J].吉林中医药,2005,25(11)：39.
[112]邢玉霞.中药治疗子宫内膜异位症痛经58例[J].实用中医药杂志,2005,21(3)：154.
[113]赵安平.月经周期辨证用药治疗痛经128例[J].陕西中医,2006,27(6)：676-677.
[114]张文红,韩士英.消异止痛煎治疗子宫内膜异位症130例临床观察[J].山西中医学院学报, 2005,6(1)：30.
[115]王世友,赵良倩,宋敏,等.异位消痛剂治疗子宫内膜异位症引发的痛经临床观察[J].湖北中医杂志,2004,26(9)：17-18.
[116]杨渐.中药灌肠治疗子宫内膜异位症50例[J].陕西中医,2005,26(10)：1007.
[117]罗幼锐.中药直肠滴入治疗子宫内膜异位症痛经78例[J].昆明医学院学报,2006,27(3)：101-102.
[118]丁哲,丁岩.耳穴贴压治疗痛经68例[J].中国民间疗法,2004,12(11)：18-19.
[119]熊运碧,祝育德.低频治疗仪治疗子宫内膜异位症所致痛经的疗效观察[J].北京中医药大学学报,2006,13(3)：23-24.
[120]陈林兴,马伟光,熊磊等.彝族验方痛经帖治疗痛经的临床观察[J].中华中医杂志,2006,21(12)：784-785.
[121]汪慧敏,王幸儿.七厘散穴位敷贴治疗子宫内膜异位症的临床观察[J].上海针灸杂志,2003,22(4)：24-25.
[122]黄艳春,谢守平.异痛宁栓治疗子宫内膜异位痛经32例临床体会[J].现代医药卫生,2002,18(5)：405.
[123]孟强,张悦.足底按摩治疗子宫内膜异位症之痛经38例[J].按摩与导引,2001,17(2)：55.
[124]王丽,阴慧琴.中药保留灌肠与口服序贯治疗子宫内膜异位症36例[J].山西中医学院学报,2009,10(1)：30-31.
[125]刘艳霞,李秀荣.中医综合子宫内膜异位症31例疗效观察[J].临床和实验医学杂志,2006,5(1)：61.
[126]韩秀兰,王楚怀,赖建洋.超声电导仪治疗慢性疼痛的临床观察[J].现代医学仪器与运用,2008,20(3)：18-20.
[1]曹泽颜.中华妇产科学[M].北京：人民卫生出版社,2004：760.
[2]夏桂成.夏桂成实用妇产科学[M].中国中医药出版社,2009：210.
[3]胡浴桓主编.疼痛心理学[M].乌鲁木齐：新疆维吾尔自治区科学技术卫生出版社,1999：44-45.
[4]中华人民共和国卫生部.中药新药临床研究指导原则[S].1993：267-271.
[5]蒋红清.子宫内膜异位症药物及生物治疗新进展[J].现代妇产科进展,2006,15(2)：134-136.
[6]安福丽,张仲,康兰芳,等.肉桂挥发性成分抑制小鼠离体子宫收缩的研究[J].河北医药,2009,31(13)：1544-1545.
[7]董学,姚庆强.中药三棱的化学成分及药理研究进展[J].齐鲁药事,2005,24(10)：612-614.
[8]赵艺,杨汝刚,罗岷.莪术油的药理作用及临床应用研究进展[J].实用中医内科杂志,2006,20(2)：125-126.
[9]唐旭刚,黄文权.五灵脂药理及临床应用概述[J].中国中医急症,2008,17(1)：101-102.
[10]王海波,王章元.蒲黄药理作用的研究进展[J].医药导报,2005,24(4)：318-319.
[11]林巧,杨大国.赤芍药理作用与临床应用的研究进展[J].中华医学研究杂志,2006,6(6)：642-644.
[12]晏媛,郑萍.续断的药理学研究进展[J].中医药研究,2002,18(5)：53-54.
[13]简秀梅.牡丹皮的药理研究与临床新用[J].中国误诊学杂志,2008,8(22)：5521-5522.
[14]付起凤,张艳丽,许树军,等.小茴香化学成分及药理作用的研究进展[J].中医药信息,2008,25(5)：24-26.
[15]李见春,黄继汉,桂长青,等.元胡止痛栓镇痛作用的实验研究[J].中国临床药理学与治疗学,2004,(4)：459-463.
[16]刘广省.益母草的药理研究进展[J].中药材,2002,25(1)：71-72.
[17]楼征亮,武耀光.复方当归注射液药理作用和临床研究进展[J].亚太传统医药,2006,(4)：73-75.
[2]Szpak R, Bugala-Szpak J, et al. Health-related quality of life in women with endometriosis[J]. Wiad Lek, 2009,62 (2):129-134.
[3]郎景和,谭先杰.第七届国际子宫内膜异位症会议纪要[J].国外医学妇产科学分册,2001,28(1)：40-43.
[4]Tsutsumi O. Assessment of human contamination of estrogenic endocrine-disrupting chemicals and their risk for human reproduction[J].J Steroid Biochem Mol Biol,2005,93 (2-5):325-330.
[5]郎景和.关于子宫内膜异位症的再认识及其意义[J].中国工程科学2009,(10)：138-142.
[6]Luisi S, Lazzeri L, Ciani V, et al. Endometriosis in Italy:from cost estimates to new medical treatment[J]. Gynecol Endocrinol,2009,25 (11):734-40.
[7]Garcia Manero M, Olartecoechea B, Royo Manero P, et al. Endometriosis[J]. Rev Med Univ Navarra, 2009,53 (2):4-7.
[8]王建华.子宫内膜异位症在位内膜酶分子表达研究进展[J].国外医学妇产科学分册,2004,31(2)：67-70.
[9]Ishihara H, Kitawaki J, Kado N, et al. Gonadotropin-releasing hormone agonist and danazol normalize cytochrome P-450 expression in eutopic endometrium from women with endometriosis,adenomyosis,or leiomyomas[J].Fertil Steril,2003,79 (Suppl 1):735-742.
[10]Zeitoun K, Takayama K, Michael MD, et al. Stimulation of aromatase P450 promoter(Ⅱ) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-Ⅰ and chicken ovalbumin upstream promoter transcription fator to the same cis-acting element[J]. Mol Endocrinol,1999,13 (2):239-253.
[11]Noble LS, Takayama K, Putman JM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells[J]. J Clin Endocrinol Metab,1997,82 (2):600-606.
[12]Tamura M, Deb S, Sebastian S, et al. Estrogen up-regulates cyclo-oxygenase-2 via estrogen receptor in human uterin microvascular endothelial cells[J]. Fertil Steril,2004,81 (5):1351-1356.
[13]Yang S, Fang Z, Suzuki T, et al. Regulation of aromatase P450 expression in endometriotic and endometrial stromal cells by CCAAT/enhancer binding proteins(C/EBPs):decreased C/EBP betain endometriosis is associated with overexpression of aromatase[J]. J Clin Endocrinol Metab,2002,87 (5):2336-2345.
[14]Gurates B, Sebastian S, Yang S, et al. WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells[J]. J Clin Endocrinol Metab,2002,87 (9):4369-4377.
[15]Holloway AC, Stys KA, Foster WG. DDE-induced changes in aromatase activity in endometrial stromal cells in culture[J]. Endocrine,2005,27 (1):45-50.
[16]Casey M L, MacDonald P C, Andersson S.17p-hydroxysteroid dehydrogenase type 2 chromosomal assignment and progestin regulation of gene expression in human endometrium[J]. J Clin Invest,1994, 94 (5):2135-2141.
[17]Yang S, Fang Z, Gurates B, et al. Stromal PRs mediate induction of 17β-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium:A paracrine mechanism for in-activation of E2[J]. Mol Endocrinol,2001,15 (12):2093-2105.
[18]曲军英,欧湘红,等.17 β-羟甾类固醇脱氢酶Ⅱ在异位子宫内膜的表达缺陷及其意义[J].福建医科大学学报,2008,42(1)：80-82.
[19]Mylonas I, Jeschke U, Shabani N, et al. Immunohistochemical analysis of estrogen receptor alpha, estrogen receptor beta and progesterone receptor in normal human endometrium[J]. Acta Histochem, 2004,106 (3):245-252.
[20]Bain DL, Franden MA, McManaman JL, et al. The N-terminal region of human progesterone B-receptors:biophysical and biochemical comparison to A-receptors[J]. J Biol Chem,2001,276 (26):23825-23831.
[21]Selak V, Farquhar C, Prentice A, et al. Danazol for pelvic pain associated with endometriosis[J]. Cochrane Database Syst Rev,2000, (2):CD000068.
[22]Mulayim N, Palter SF, Kayisli UA, et al. Chemokine receptor expression in human endometrium[J]. Biol .Reprod,2003,68 (5):1491-1495.
[23]Kayisli UA, Mahutte NG, Arici A. Uterine chemokines in reproductive physiology and pathology[J]. Am J Reprod Immunol,2002,47 (4):213-221.
[24]Mulayim N, Savlu A, Guzeloglu-kayisi O, et al. Regulation of endometrial stromal cell matrix metalloproteinase activity and invasiveness by interleukin-8[J]. Fertil Steril,2004,81 (Suppl1):904-911.
[25]Calhaz-Jorge C, Costa AP, Santos MC, et al. Peritoneal fluid concentrations of interleukin-8 in patients with endometriosis depend on the severity of the disorder and are higher in the luteal phase[J]. Hum Reprod,2003,18(3):593-597.
[26]黄丛笑,刘萍,张居民.纤维粘连蛋白及其受体整合素β1在子宫内膜异位症中的表达[J].中国实用医药,2009,4(1)：124.
[27]史颖莉,李大金.趋化因子在子宫内膜异位症发生与发展中的作用[J].国外医学妇产科学分册,2004,31(5)：305-308.
[28]Sakamoto Y, Harada T, Horie S, et al. Tumor necrosis factor-alpha-induced interleukin-8 (IL-8)expression in endometriotic stromal cells,probably through nuclear factor-kappa B activation:gonadotropin-releasing hormone agonist treatment reduced IL-8 expression[J]. J Clin Endocrinol Metab,2003,88 (2):730-735.
[29]熊苗,屠菊红,赵爱民.趋化因子及其受体与子宫内膜异位症的关系[J].中国妇幼健康研究,2006,17(6)：516-518.
[30]郭小明,唐显赫,张学辉.单核细胞趋化蛋白在子宫内膜异位症中的作用研究进展[J].中国煤炭工 业医学杂志,2008,11(2)：278-279.
[31]Kharfi A, Akoum A. Correlation between decreased type-Ⅱ interleukin-1 receptor and increased monocyte chemotactic protein-1 expression in the endometrium of women with endometriosis[J]. Am J Reprod Immunol,2001,45 (4):193-199.
[32]Hornung D, Bentzien F, Wallwiener D, et al. Chemokine bioactivity of RANTES in endometriotic and normal endometrial stromal cells and peritoneal fluid[J]. Mol Hum Reprod,2001,7 (2):163-168.
[33]Dechaud H, Witz CA, Montoya-Rodriguez IA, et al. Mesothelial cell-associated hyaluronic acid promotes adhesion of endometrial cells to mesothelium[J]. Fertil Steril,2001,76 (5):1012-1018.
[34]Whiteside EJ, Jackson MM, Herington AC, et al. Matrix metalloproteinases-9 and inhibitor of metalloproteinases-3 are key regulators of extracelluar matrix degradation by mouse embryos[J]. Biol Reprod,2004,64 (5):1331-1337.
[35]Kokorine I, Eeckhout Y, Nisolle M, et al. Expression of interstitial collagenase (matrix metalloproteinase-1) is related to the activity of human endometriotic lesions[J]. Fertil Steril,1997,68 (2):246-251.
[36]Kim HO, Yang KM, Kang IS, et al. Expression of CD44s,vascular endothelial growth factor, matrix metalloproteinase-2 and Ki-67 in peritonea,rectovaginal and ovarian endometriosis[J]. J Reprod Med, 2007,52 (3):207-213.
[37]Ramon L, Gilabert-estelles J, Castello R, et al. mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay[J]. Hum Reprod,2005,20 (1):272-278.
[38]Collette T, Maheux R, Mailloux J, et al. Increased expression of matrix metalloproteinase-9 in the eutopic endometrial tissue of women with endometriosis[J]. Hum Reprod,2006,21 (12):3059-3067.
[39]Bourguignon LY, Gunja-Smith Z, Iida N, et al. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breas cancer cells[J].J Cell physiol,1998,176 (1):206-215.
[40]Laudanski P, Szamalowjcz J, Ramel P. Matrix metalloproteinase-13 and membrane type-1 matrix metalloproteinase in peritoneal fluid of women with endometriosis [J]. Gynecol Endocrinol,2005,21 (2):106-110.
[41]Kang S, Wang Y, Zhang JH, et al. Single nucleotide polymorphism in the matrix metalloproteinases promoter is associated with susceptibility to endometriosis and adenomyosis[J]. Zhonghua Fu Chan Ke Za Zhi,2005,40 (9):601-604.
[42]Shan K, Lian-Fu Z, Hui D, et al. Polymorphisms in the promoter regions of the matrix metalloproteinases-7,-9 and the risk of endometriosis and adenomyosis in China[J]. Mol Hum Reprod, 2006,12 (1):35-39.
[43]Chung HW, Wen Y, Chun SH, et al. Matrix metaloproteinase-9 and tissue inhibitor of metalloproteinase-3 mRNA expression in eutopic and eutopic endometrium in women with endometriosis:a rationale for endometriotic invasiveness[J]. Fertil Steril,2004,75 (1):152-159.
[44]Goffin F, Munaut C, Frankenne F, et al. Expression pattern of metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human endometrium[J]. Biol Reprod,2003,69 (3):976-984.
[45]周小会,李兆艾.子宫内膜异位症患者腹腔液中MMP-1和TMP-1的检测[J].江苏医药,2007,33(1)：32-33.
[46]沈蓉,田永杰.MMP-9、TIMP-1在子宫内膜异位症患者子宫内膜中的表达及意义[J].山东医药,2006,46(17)：20-22.
[47]Sillem M, Prifti S, Koch A, et al. Regulation of matrix metalloproteinases and their inhibitors in uterine endometrial cells of patients with and without endometriosis[J]. Eur J Obstet Gynecol Reprod Biol,2001, 95 (2):167-174.
[48]Noguchi Y, Sato T, Hirata M, et al. Identification and characterization of extracellular matrix metalloproteinase inducer in human endometrium during the menstrual cycle in vivo and in vitro[J]. J Clin Endocrinol Metab,2003,88 (12):6063-6072.
[49]刘木彪,何援丽,麦冬先.子宫内膜异位症患者腹腔液血管内皮生长因子与内抑素的表达[J].第一军医大学学报,2004,24(1)：69-71.
[50]Mahnke JL, Dawood MY, Huang JC. Vascular endothelial growth factor and interleukin-6 in peritoneal fluid of women with endometriosis[J]. Fertil Steril,2000,73 (1):166-170.
[51]Nap AW, Griffioen AW, Dunselman GA, et al. Antiangiogenesis therapy for endometriosis [J]. J Clin Endocrinol Metab,2004,89 (3):1089-1095.
[52]Saitoh Y, Yaginuma Y, Ishikawa M. Analysis of Bcl-2,Bax and Survivin genes in uterine cancer[J]. Int J Oncol,1999,15 (1):137-141.
[53]Ferrero S, Gillott DJ, Anserini P, et al. Methodological concerns regarding levels of vascular endothelial growth factor(VEGF) in serum of patients with endometriosis [J]. Hum Reprod,2008,19(1):220-221.
[54]van de Kerkhof PC, Rulo HF, van Pelt JP, et al. Expression of endoglin in the transition between psoriatic uninvolved and involved skin[J]. Acta Derm Venereol,1998,78 (1):19-21.
[55]任旭,何援利,彭冬先.缺氧诱导因子-1 α在子宫内膜异位症中的表达与微血管密度的关系[J].广东医学,2007,28(2)：229-231.
[56]Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis[J]. J Natl Cancer Inst,2001,93 (4):309-314.
[57]Fujimoto J, Sakaguchi H, Hirose R, et al. Angiogenesis in endometriosis and angiogenic factors[J]. Gynecol Obstet Invest,1999,48(1):14-20.
[58]Talbi S, Hamilton AE, Vo KC, et al. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women[J]. Endocrinology,2006,147 (3):1097-1121.
[59]Brown LF, Detmar M, Tognazzi K, et al. Uterine smooth muscle cells express functional receptors(flt-1 and KDR)for vascular permeability factor/vascular endothelial growth factor[J]. Lab Invest,1997,76 (2):245-255.
[60]Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential[J].Microvasc Res,2002,64 (2):326-333.
[61]Matsuzaki S, Canis M, Yokomizo R, et al. Expression of erythropoietin and erythropoietin receptor in eritoneal endometriosis[J]. Hum Reprod,2003,18 (1):152-156.
[62]胡瑞成,谭双香.缺氧诱导因子1蛋白质水平及活性的调节[J].国外医学分子生物学分册,2003,3：99-102.
[63]Hayrabedyan S, Kyurkchiev S, Kehayov I. Endoglin (cd105) and S100A13 as markers of active angiogenesis in endometriosis[J]. Reprod Biol,2005,5 (1):51-67.
[64]Zhou H, Wang W, LuoY. Contributions of disulfide bonds in a nested pattem to the structure,stability,and biological functions of endostatin[J]. J Biol Chem,2005,280 (12):11303-11312.
[65]Liu MB, He YL, Peng DX. Expression of vascular endothelial growth factor and endostain in peritoneal fluid of patients with endometriosis[J]. Di Yi Jun Yi Da Xue Xue Bao,2004,24 (1):69-71.
[66]Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancenassociation with p53 alterations,tumor angiogenesis,and tumor progression[J]. J Natl Cancer Inst,1997,89 (3):219-227.
[67]Maeda K, Nishiguchi Y, Yashiro M, et al. Expression of vascular endothelial growth factor and thrombospondin-1 in colorectal carcinoma[J]. Int J Mol Med,2000,5 (4):373-378.
[68]谭先杰,郎景和,刘东远,等.血管内皮生长因子及血小板反应素在异位子宫内膜组织中的表达[J].中华妇产科杂志,2001,36(12)：727-730.
[69]王云霞,李亚里,黄靖香.凋亡调节基因bcl-2,bax和fas在子宫内膜异位症中的表达[J].解放军医学杂志,2001,26(1)：69-70.
[70]Kuida K, Haydar TF, Kuan CY, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase-9[J]. Cell,1998,94 (3):325-337.
[71]Dmowski WP, Ding J, Shen J, et al. Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis[J]. Hum Reprod,2001,16 (9):1802-1808.
[72]王平,边爱平,段瑞丽.子宫内膜异位症患者子宫内膜caspase-3的表达研究[J].实用诊断与治疗杂志,2006,20(4)：242-243.
[73]Ueda M, Yamashita Y, Takehara M, et al. Survivin gene expression in endometriosis[J]. J Clin Endocrinol Metab,2002,87 (7):3452-3459.
[74]Suzuki A, Hayashida M, Ito T, et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p 16 (IN K4a) and Cdk2/cyclin E complex activation[J]. Oncogene,2000,19 (29):3225-3234.
[75]Fraser AG, James C, Evan GI, et al. Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis[J]. Curr Biol,1999,9(6):292-301.
[76]Sanna MG, da Silva Correia J, Ducrey O, et al. IAP suppression of apoptosis involves distinct mechanisms:the TAK1/JNK1 signaling cascade and caspase inhibition[J]. Mol Cell Biol,2002,22 (6): 1754-1766.
[77]王春芳,边爱平.Livin和Caspase-9在子宫内膜异位症中的表达[J].中国妇产科临床杂志,2009,10(2)：127-130.
[78]Kalu E, Sumar N, Giannopoulos T, et al. Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis[J]. J Obstet Gynaecol Res,2007,33 (4):490-495.
[79]Had RS, Fleming SD, Bebington CR, et al. Ubiquitin is associated with the survival of ectopic stromal cells in endometriosis[J]. Reprod Biol Endocrinol,2004,2 (1):69-73.
[80]Banerjee M, Dinda AK, Sinha S, et al. C-myc oncogene expression and cell proliferation in mixed oligo-astrocytoma[J]. Int Cancer,1996,65 (6):730-733.
[81]刘俊达,张靖莲.细胞凋亡研究促进新药开发的展望[J].中国新药杂志,1999,8(5)：298.
[82]Bischoff FZ, Heard M, Simpson JL. Somatic DNA alterations in endometriosis:high frequency of chromosome 17 and p53 loss in late-stage endometriosis[J]. J Reprod Immunol,2002,55 (1-2):49-64.
[83]Braun DP, Ding J, Shen J, et al. Relationship between apoptosis and the number of macrophages in eutopic endometrium from womenwith and without endometriosis[J]. Fertil Steril,2002,78 (4):830-835.
[84]Mutter GL, Lin MC, Fitzgerald JT, et al. Changes in endometrial PTEN expression throughout the human menstrual cycle[J]. J Clin Endocrinol Metab,2000,85 (6):2334-2338.
[85]Nishida M, Nasu K, Ueda T, et al. Endometriotic cells are resistant to interferon-gamma-induced cell growth inhibition and apoptosis:a possible mechanism involved in the pathogenesis of endometriosis[J]. Mol Hum Reprod,2005,11 (1):29-34.
[86]Van Langendonckt A, Casanas Roux F, Donnez J, et al. Oxidative stress and petitoneal endometriosis[J]. Fertil Steril,2002,77 (5):861-870.
[87]Ota H, Igarashi S, Tanaka T. Xanthine oxidase in eutopic and ectopic endometrium in endometriosis and adenomyosis[J]. Fertil Steril,2001,75 (4):785-790.
[88]Gallinelli A, Chiossi G, Giannella L, et al. Different concentrations of interleukins in the peritoneal fluid of women with endometriosis:relationships with lymphocyte subsets[J]. Gynecol Endocrinol,2004,18 (3):144-151.
[89]Oosterlynck DJ, Meuleman C, Waer M, et al. The natural killer activity of peritoneal fluid lymphocytes is decreased in women with endometriosis[J]. Fertil Steril,1992,58 (2):290-295.
[90]令狐华,徐小蓉,卞度宏.子宫内膜异位症患者外周血及腹腔中自然杀伤细胞活性的测定[J].中华妇产科杂志,1996,31：586-589.
[91]Prefumo F, Semino C, Melioli G, et al. A defective expression of ICAM-1 (CD54) on secretory endometrial cells is associated with endometriosis[J]. Immunol Lett,2002,80 (1):49-53.
[92]Berkkanoglu M, Arici A. Immunology and endometriosis[J]. Am J Reprod Immunol,2003,50(1):48-59.
[93]Kayisli UA, Mahutte NG, Arici A. Uterine chemokines in reproductive physiology and pathology[J]. Am J Reprod Immunol,2002,47 (4):213-221.
[94]Koike H, Egawa H, Ohtsuka T, et al. Correlation between dysmenorrheic severity and prostaglandin production in women with endometriosis[J]. Prostaglandins Leukot Essent Fatty Acids,1992,46 (2): 133-137.
[95]孙笑,周应芳.TGF-β1与子宫腺肌病痛经的相关性研究实验与基础研究[J].中国妇幼保健,2008,23(1)：73-74.
[96]江森.子宫内膜异位症研究的进展[J].中华妇产科杂志,1994,10(2)：624.
[97]Tahara A, Tsukada J, Tomura Y, et al. Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells[J]. British Journal of Pharmacology,2000,129 (1):131-139.
[98]Gimpl G, Fshrenholz F. The Oxytocin Receptor System:Structure,Function,and Regulation[J]. Physiological Reviews,2001,81(2):629-683.
[99]Oku H, Tsuji Y, Kashiwamura SI, et al. Role of IL-18 in pathogenesis of endometriosis[J]. Hum Reprod, 2004,19 (3):709-714.
[100]岳天孚,刘晓玫.子宫内膜异位症与盆腔痛[J].中华实用妇产科与产科杂志,1999,10(3)585-587.
[101]徐传花,夏桂成.夏桂成治疗子宫内膜异位症所致痛经的经验[J].中国中医药信息杂志,2003,10(5)：70.
[102]卫爱武.韩冰治疗子宫内膜异位症经验[J].北京中医杂志,2003,22(1)：13.
[103]岳小强,史学文.子宫内膜异位症从脾论治探讨[J].时珍国医国药,2001,12(3)：238.
[104]王雨波.温阳化瘀法治疗盆腔子宫内膜异位症疗效观察[J].四川中医,2007,25(5)：79-80.
[105]付淑秀,路臻,高天雨.补脾祛瘀方治疗子宫内膜异位症46例[J].中医药临床杂志,2007,19(3)：230.
[106]黄艳辉,曹立幸,司徒仪.莪棱胶囊治疗气滞血瘀型子宫内膜异位症临床研究[J].上海中医药杂志,2008,42(3)：46-48.
[107]徐玲,焦锟.宣郁通经汤化裁治疗肝郁血热型痛经48例[J].江苏中医药,2008,40(11)：69.
[108]毕蓉蓉.中医治疗子宫内膜异位症探讨[J].中国血液流变学杂志,2001,11(1)：69-71.
[109]吴凡,祖玉梅.辨证治疗子宫内膜异位症53例[J].辽宁中医杂志,1997,24(3)：122-123.
[110]张灵芳,罗杏娟.王金生治疗子宫内膜异位症经验[J].现代中西医结合杂志,2007,16(25)：3710.
[111]张俐,刘平,刘红艳.中药治疗子宫内膜异位症29例[J].吉林中医药,2005,25(11)：39.
[112]邢玉霞.中药治疗子宫内膜异位症痛经58例[J].实用中医药杂志,2005,21(3)：154.
[113]赵安平.月经周期辨证用药治疗痛经128例[J].陕西中医,2006,27(6)：676-677.
[114]张文红,韩士英.消异止痛煎治疗子宫内膜异位症130例临床观察[J].山西中医学院学报, 2005,6(1)：30.
[115]王世友,赵良倩,宋敏,等.异位消痛剂治疗子宫内膜异位症引发的痛经临床观察[J].湖北中医杂志,2004,26(9)：17-18.
[116]杨渐.中药灌肠治疗子宫内膜异位症50例[J].陕西中医,2005,26(10)：1007.
[117]罗幼锐.中药直肠滴入治疗子宫内膜异位症痛经78例[J].昆明医学院学报,2006,27(3)：101-102.
[118]丁哲,丁岩.耳穴贴压治疗痛经68例[J].中国民间疗法,2004,12(11)：18-19.
[119]熊运碧,祝育德.低频治疗仪治疗子宫内膜异位症所致痛经的疗效观察[J].北京中医药大学学报,2006,13(3)：23-24.
[120]陈林兴,马伟光,熊磊等.彝族验方痛经帖治疗痛经的临床观察[J].中华中医杂志,2006,21(12)：784-785.
[121]汪慧敏,王幸儿.七厘散穴位敷贴治疗子宫内膜异位症的临床观察[J].上海针灸杂志,2003,22(4)：24-25.
[122]黄艳春,谢守平.异痛宁栓治疗子宫内膜异位痛经32例临床体会[J].现代医药卫生,2002,18(5)：405.
[123]孟强,张悦.足底按摩治疗子宫内膜异位症之痛经38例[J].按摩与导引,2001,17(2)：55.
[124]王丽,阴慧琴.中药保留灌肠与口服序贯治疗子宫内膜异位症36例[J].山西中医学院学报,2009,10(1)：30-31.
[125]刘艳霞,李秀荣.中医综合子宫内膜异位症31例疗效观察[J].临床和实验医学杂志,2006,5(1)：61.
[126]韩秀兰,王楚怀,赖建洋.超声电导仪治疗慢性疼痛的临床观察[J].现代医学仪器与运用,2008,20(3)：18-20.
[1]曹泽颜.中华妇产科学[M].北京：人民卫生出版社,2004：760.
[2]夏桂成.夏桂成实用妇产科学[M].中国中医药出版社,2009：210.
[3]胡浴桓主编.疼痛心理学[M].乌鲁木齐：新疆维吾尔自治区科学技术卫生出版社,1999：44-45.
[4]中华人民共和国卫生部.中药新药临床研究指导原则[S].1993：267-271.
[5]蒋红清.子宫内膜异位症药物及生物治疗新进展[J].现代妇产科进展,2006,15(2)：134-136.
[6]安福丽,张仲,康兰芳,等.肉桂挥发性成分抑制小鼠离体子宫收缩的研究[J].河北医药,2009,31(13)：1544-1545.
[7]董学,姚庆强.中药三棱的化学成分及药理研究进展[J].齐鲁药事,2005,24(10)：612-614.
[8]赵艺,杨汝刚,罗岷.莪术油的药理作用及临床应用研究进展[J].实用中医内科杂志,2006,20(2)：125-126.
[9]唐旭刚,黄文权.五灵脂药理及临床应用概述[J].中国中医急症,2008,17(1)：101-102.
[10]王海波,王章元.蒲黄药理作用的研究进展[J].医药导报,2005,24(4)：318-319.
[11]林巧,杨大国.赤芍药理作用与临床应用的研究进展[J].中华医学研究杂志,2006,6(6)：642-644.
[12]晏媛,郑萍.续断的药理学研究进展[J].中医药研究,2002,18(5)：53-54.
[13]简秀梅.牡丹皮的药理研究与临床新用[J].中国误诊学杂志,2008,8(22)：5521-5522.
[14]付起凤,张艳丽,许树军,等.小茴香化学成分及药理作用的研究进展[J].中医药信息,2008,25(5)：24-26.
[15]李见春,黄继汉,桂长青,等.元胡止痛栓镇痛作用的实验研究[J].中国临床药理学与治疗学,2004,(4)：459-463.
[16]刘广省.益母草的药理研究进展[J].中药材,2002,25(1)：71-72.
[17]楼征亮,武耀光.复方当归注射液药理作用和临床研究进展[J].亚太传统医药,2006,(4)：73-75.